Livzon Pharmaceutical Group (HK:1513) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Livzon Pharmaceutical Group Inc. has just received approval from the National Medical Products Administration for a new indication of their drug, Triptorelin Acetate Microspheres for Injection, specifically for the treatment of endometriosis. This marks a significant milestone for the company, expanding the potential market for their product and offering a new therapeutic option for individuals suffering from this condition.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
